BamSEC and AlphaSense Join Forces
Learn More

Amneal Pharmaceuticals Inc. – Plans of Reorganization, Merger, Acquisition or Similar

NASDAQ: AMRX    
Share price (5/22/26): $12.42    
Market cap (5/22/26): $3.962 billion
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 133 pages Membership Interest Purchase Agreement Dated as of April 21, 2026 by and Among Kashiv Biosciences, LLC, (The “Company”), the “Sellers” Named Herein, Kb Seller Representative, LLC (The “Seller Representative”), and Amneal Pharmaceuticals, Inc
12/34/56
EX-2.2
from 8-K12B 65 pages Agreement and Plan of Merger by and Among Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC and Amneal Merger Sub 2 LLC Dated as of November 7, 2023
12/34/56
EX-2.1
from 8-K12B 26 pages Agreement and Plan of Merger by and Among Amneal Pharmaceuticals, Inc., Amneal Newco Inc. and Amneal Merger Sub 1 Inc. Dated as of November 7, 2023
12/34/56
EX-2.5
from 10-K 36 pages In Accordance With the Securities and Exchange Commission Rules, Certain Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. Brackets With Asterisks Denote Omissions (I.E., [***]). Share Purchase Agreement Amongst Amneal Pharmaceuticals Private Limited and the Persons Listed in Schedule I and Puniska Healthcare Private Limited November 2, 2021
12/34/56
EX-2.1
from 8-K 86 pages Asset Purchase Agreement Among Saol International Limited, Saol Therapeutics Research Limited, Saol Therapeutics Inc., Saol International Research Limited, Saol International Development Limited, Emerald International Limited, Emerald Therapeutics Research Limited and Amneal Pharmaceuticals LLC Dated as of December 30, 2021
12/34/56
EX-2.1
from 8-K 82 pages Membership Interest Purchase Agreement Dated as of January 11, 2021 by and Between Kashiv Biosciences, LLC (“Seller”) and Amneal Pharmaceuticals LLC
12/34/56
EX-2.3
from 8-K 43 pages Guaranty and Security Agreement Dated as of January 31, 2020 Made by Rondo Intermediate Holdings, LLC as Borrower and the Other Grantors From Time to Time Party Hereto in Favor of Truist Bank as Administrative Agent
12/34/56
EX-2.2
from 8-K 158 pages Revolving Credit and Term Loan Agreement Dated as of January 31, 2020 Among Rondo Intermediate Holdings, LLC as Borrower, Rondo Holdings, LLC, as Holdings, the Lenders From Time to Time Party Hereto, and Truist Bank as Administrative Agent Suntrust Robinson Humphrey, Inc., Bofa Securities, Inc., Rbc Capital Markets and City National Bank, as Joint Bookrunners and Joint Lead Arrangers
12/34/56
EX-2.1
from 8-K 55 pages Amended and Restated Operating Agreement of Rondo Partners, LLC Dated as of January 31, 2020
12/34/56
EX-2.1
from 8-K 99 pages Equity Purchase Agreement Among Steve Shirley Business Trust, Jerry Shirley Business Trust, Jerry Brian Shirley Business Trust, Darren Thomas Shirley Business Trust, Troy Mizell, Darrell Calvert, Dixon-Shane LLC D/B/a R&S Northeast LLC, Avkare, Inc. and Rondo Acquisition LLC Dated as of December 10, 2019
12/34/56
EX-2
from SC 13D 52 pages Share Purchase Agreement Among Amneal Holdings, LLC and the Purchasers Party Hereto October 17, 2017
12/34/56
EX-2.4
from S-1 51 pages November 21, 2017 Tpg Improv Holdings, L.P. C/O Tpg Partners VII, L.P. 301 Commerce Street Suite 3300 Fort Worth, Tx 76102 Re: Letter Agreement Ladies and Gentlemen
12/34/56
EX-2.3
from S-1 6 pages Amendment No. 2 to the Business Combination Agreement
12/34/56
EX-2.2
from S-1 9 pages Amendment No. 1 to the Business Combination Agreement
12/34/56
EX-2.2
from 8-K 58 pages Purchase and Sale Agreement by and Among Amneal Pharmaceuticals LLC, Gemini Laboratories, LLC, the Persons Signatory Hereto as Sellers and the Sellers’ Representative Dated as of May 7, 2018
12/34/56
EX-2.1
from S-1 128 pages Business Combination Agreement Dated as of October 17, 2017 by and Among Impax Laboratories, Inc., Atlas Holdings, Inc., K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC
12/34/56
EX-2.4
from S-1/A 51 pages November 21, 2017 Tpg Improv Holdings, L.P. C/O Tpg Partners VII, L.P. 301 Commerce Street Suite 3300 Fort Worth, Tx 76102 Re: Letter Agreement Ladies and Gentlemen
12/34/56
EX-2.3
from S-1/A 6 pages Amendment No. 2 to the Business Combination Agreement
12/34/56
EX-2.2
from S-1/A 9 pages Amendment No. 1 to the Business Combination Agreement
12/34/56
EX-2.1
from S-1/A 128 pages Business Combination Agreement Dated as of October 17, 2017 by and Among Impax Laboratories, Inc., Atlas Holdings, Inc., K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC
12/34/56